CA2705373A1 - Hiv-1 envelope glycoprotein oligomer and methods of use - Google Patents

Hiv-1 envelope glycoprotein oligomer and methods of use Download PDF

Info

Publication number
CA2705373A1
CA2705373A1 CA2705373A CA2705373A CA2705373A1 CA 2705373 A1 CA2705373 A1 CA 2705373A1 CA 2705373 A CA2705373 A CA 2705373A CA 2705373 A CA2705373 A CA 2705373A CA 2705373 A1 CA2705373 A1 CA 2705373A1
Authority
CA
Canada
Prior art keywords
polypeptide
fusion polypeptide
fusion
r2gp140
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2705373A
Other languages
English (en)
French (fr)
Inventor
Gerald Quinnan
Christopher Broder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M. Jackson Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2705373A1 publication Critical patent/CA2705373A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2705373A 2007-11-12 2008-11-12 Hiv-1 envelope glycoprotein oligomer and methods of use Abandoned CA2705373A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98728707P 2007-11-12 2007-11-12
US60/987,287 2007-11-12
PCT/US2008/083190 WO2009102357A2 (en) 2007-11-12 2008-11-12 Hiv-1 envelope glycoprotein oligomer and methods of use

Publications (1)

Publication Number Publication Date
CA2705373A1 true CA2705373A1 (en) 2009-08-20

Family

ID=40957413

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2705373A Abandoned CA2705373A1 (en) 2007-11-12 2008-11-12 Hiv-1 envelope glycoprotein oligomer and methods of use

Country Status (6)

Country Link
US (1) US8597658B2 (cg-RX-API-DMAC7.html)
EP (1) EP2235065A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011502521A (cg-RX-API-DMAC7.html)
AU (1) AU2008350273B2 (cg-RX-API-DMAC7.html)
CA (1) CA2705373A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009102357A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2877205A4 (en) * 2012-07-26 2016-04-06 Jackson H M Found Military Med VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY
CN109153704A (zh) * 2016-05-02 2019-01-04 斯克里普斯研究学院 与hiv-1免疫原相关的组合物和方法
AU2018366480C1 (en) * 2017-11-17 2024-02-01 Grifols Diagnostic Solutions Inc. Novel mammalian expressed human immunodeficiency virus envelope protein antigens

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292646A (en) * 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US6039957A (en) 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
ATE435034T1 (de) * 1998-08-04 2009-07-15 Jackson H M Found Military Med Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.
WO2001019958A2 (en) * 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Stabilized soluble glycoprotein trimers
WO2003077838A2 (en) 2002-03-05 2003-09-25 National Institutes Of Health Office Of Technology Transfer Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens
AU2005280004B2 (en) * 2004-08-27 2012-02-23 Institute Of Tropical Medicine Modified HIV-1 envelope proteins

Also Published As

Publication number Publication date
AU2008350273A1 (en) 2009-08-20
AU2008350273B2 (en) 2014-04-10
US20100316661A1 (en) 2010-12-16
EP2235065A4 (en) 2011-09-28
WO2009102357A3 (en) 2009-10-22
JP2011502521A (ja) 2011-01-27
EP2235065A2 (en) 2010-10-06
WO2009102357A2 (en) 2009-08-20
US8597658B2 (en) 2013-12-03

Similar Documents

Publication Publication Date Title
US12344661B2 (en) Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination
ES2635080T3 (es) Vacunas contra el cáncer dirigidas a células presentadoras de antígenos
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6643981B2 (ja) インフルエンザウイルスワクチンおよびその使用
US20210009640A1 (en) Compositions comprising hiv envelopes to induce hiv-1 antibodies
AU2018202997A1 (en) DNA antibody constructs and method of using same
CN111542534B (zh) 新型支架式hiv-1疫苗免疫原
EP2877205A2 (en) Multimeric fusion protein vaccine and immunotherapeutic
CN105792842A (zh) 埃巴病毒疫苗
US20210379178A1 (en) Compositions comprising hiv envelopes to induce hiv-1 antibodies
US20190031721A1 (en) Soluble Forms of Hendra and Nipah Virus F Glycoprotein and Uses Thereof
PH12015500890B1 (en) Vaccine for preventing porcine edema disease
AU2008350273B2 (en) HIV-1 envelope glycoprotein oligomer and methods of use
KR20190079628A (ko) 백신으로 사용하기 위한 엑소좀-앵커링 단백질을 발현하는 뉴클레오티드 서열
US20240307524A1 (en) Coronavirus vaccines
US8475799B2 (en) HIV-1 GP41 neutralization domain and use thereof
AU2013276968B2 (en) Soluble Forms of Hendra and Nipah Virus F Glycoprotein and Uses Thereof
JP4549666B2 (ja) 抗体の製造方法
EP3104884B1 (en) A new non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection
JP2020162607A (ja) インフルエンザウイルスワクチンおよびその使用
AU2016222452A1 (en) Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131108

FZDE Discontinued

Effective date: 20160819